title: Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome.
abstract: The electrophysiologic effects of intravenous propafenone were studied in 15 consecutive patients with accessory pathways. Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained. In all except one patient, propafenone, 2 mg/kg given intravenously over a 10-minute period, was successful in converting the arrhythmia to sinus rhythm. Atrial fibrillation was inducible in 10 patients before propafenone, but was no longer inducible in seven of these patients after the drug. The HV interval (23 +/- 20 to 41 +/- 25 msec) and the anterograde (310 +/- 96 to 509 +/- 145 msec) and retrograde (256 +/- 30 to 334 +/- 105 msec) effective refractory periods of the bypass tract were all significantly prolonged after the drug. The pacing cycle length that produced conduction block over the bypass tract anterogradely (319 +/- 126 to 446 +/- 150 msec) and retrogradely (272 +/- 25 to 360 +/- 97 msec) was also increased. During orthodromic tachycardia, propafenone increased conduction time in both the anterograde and retrograde limbs of the tachycardia. Tachycardia terminated in the retrograde limb in 64% of the patients. We conclude that propafenone is very effective in terminating orthodromic tachycardia when given intravenously and that it should be considered in patients initially seen with atrial fibrillation and short refractory periods.
authors.affiliation: Department of Medicine, Sacré-Coeur Hospital, Montreal, Quebec, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Dubuc
authors.forename: T
authors.initials: T
authors.lastname: Kus
authors.forename: M A
authors.initials: MA
authors.lastname: Campa
authors.forename: C
authors.initials: C
authors.lastname: Lambert
authors.forename: M
authors.initials: M
authors.lastname: Rosengarten
authors.forename: M
authors.initials: M
authors.lastname: Shenasa
mesh_terms: D000328:Adult; D002304:Cardiac Pacing, Artificial; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004594:Electrophysiology; D006801:Humans; D007231:Infant, Newborn; D007275:Injections, Intravenous; D007545:Isoproterenol; D008875:Middle Aged; D011405:Propafenone / Q000097:blood / Q000627:therapeutic use*; D012032:Refractory Period, Electrophysiological; D013610:Tachycardia / Q000209:etiology / Q000503:physiopathology; D014927:Wolff-Parkinson-White Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D011405:Propafenone; D007545:Isoproterenol